Bold plan to diversify Alzheimer’s research takes shape; what do new Alzheimer's drug results mean for patients?

For decades, Alzheimer's researchers have recruited patients in largely the same way. Gladys Maestre came to Texas' Rio Grande Valley to change that. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     On the Texas-Mexico border, a bold plan to diversify Alzheimer's research takes shape By Usha Lee McFarling Verónica Cárdenas for STAT Residents' wariness of outsiders demonstrates the need for Alzheimer's researcher Gladys Maestre's unorthodox, community-centered approach. Read More An Alzheimer's therapy scores winning results, but what could it mean for patients? By Andrew Joseph Adobe Lecanumab succeeded in a trial, but doctors' early verdict range from "more days of independence" to "I wish I could be more impressed." Read More Virtual drug screening identifies possible new antidepressants in LSD-like molecules By Meghana Keshavan Adobe Two LSD-like chemical molecules were found to have antidepressant effects in mice, without psychedelic side effects. Read More Sponsor content by CSL Seqirus What you need to know about health economic outcomes research In order to determine a balance between the quality and cost of public health interventions, such as vaccines, healthcare systems use health economic outcomes research, or HEOR. Learn more about the common model types used to generate economic evidence to aid healthcare policy decision-making and shed light on value and affordability when evaluating new interventions. STAT+: If a new Alzheimer's drug works, was there any point to the Aduhelm controversy? Yes By Matthew Herper Molly Ferguson for STAT The Alzheimer's drug lecanemab clearly succeed in its randomized controlled trials, a reminder of all the ways in which Aduhelm didn't. Read More STAT+: A 'disaster', or a 'clear path' forward?: New FDA guidance on AI in medicine sparks strong reactions By Casey Ross Jacquelyn Martin/AP New guidance from the FDA on artificial intelligence tools is triggering strong reaction from researchers and regulatory experts. Read More Where caregiving is a family affair, Alzheimer's places a heavy burden on children and spouses By Usha Lee McFarling Verónica Cárdenas for STAT The Rio Grande Valley has some of the nation's highest rates of Alzheimer's, placing an enormous burden on Mexican American caregivers. Read More Opinion: Listen: How the Dobbs decision could affect how and where clinical trials are conducted By Patrick Skerrett The Supreme Court's decision to overturn Roe v. Wade will have many trickle-down effects. Some will change how clinical trials are conducted. Read More Opinion: Medicare needs to cover the full spectrum of care for substance use disorders By Fred Riccardi and Judith Stein and Ellen Weber Julia Nikhinson/AP Medicare covers only the least and most intensive levels of treatment for substance use disorders. It needs to cover the full spectrum. Read More STAT+: Lilly is accused by the federal government of discriminating against older sales reps By Ed Silverman This “appears to fit into the EEOC’s priority for filing lawsuits based on systemic discrimination" said Cornell University's Risa Lieberwitz Read More Wednesday, September 28, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser